AndreaBozzo/ceres-open-data-index huggingface dataset:
Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis

Epidemiological studies have established that fenfluramine, D-fenfluramine, and aminorex, but not other appetite suppressants, increase the risk of primary pulmonary hypertension (PH). One current hypothesis suggests that fenfluramine-like medications may act through interactions with the serotonin (5-hydroxytryptamine [5-HT]) transporter (5-HTT) located on pulmonary artery smooth muscle cells and responsible for the mitogenic action of 5-HT. Anorexigens may contribute to PH by boosting 5-HT levels in the bloodstream, directly stimulating smooth muscle cell growth, or altering 5-HTT expression. We suggest that individuals with a high basal level of 5-HTT expression related to the presence of the long 5-HTT gene promoter variant may be particularly susceptible to one or more of these potential mechanisms of appetite-suppressant-related PH.
Patent AT-E401758-T1: [Translated] IMPLANTABLE HEARING SYSTEM

An at least partially implantable system for rehabilitation of a hearing disorder with an arrangement for processing and/or generation of signals is provided including an implantable processor arrangement with control logic which operates according to an operating program and an implantable storage arrangement for storage of the operating program and of operating parameters. A wireless telemetry unit is provided for data transmission between the implantable part of the system and an external unit. The system also includes a power supply arrangement which supplies individual components of the system with current and a rewritable implantable storage arrangement assigned to the processor arrangement for holding and reproducing the operating program and the operating parameters. At least a part of the operating program and/or of the operating parameters can be modified and/or replaced by data transmitted from the external unit via the telemetry unit.
PLACES: ZCTA Data (GIS Friendly Format), 2021 release

This dataset contains model-based ZIP Code Tabulation Area (ZCTA) level estimates for the PLACES 2021 release in GIS-friendly format. PLACES is the expansion of the original 500 Cities Project and covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area (ZCTA) levels. It represents a first-of-its kind effort to release information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2019 or 2018 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 or 2014–2018 estimates. The 2021 release uses 2019 BRFSS data for 22 measures and 2018 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours a night). Seven measures are based on the 2018 BRFSS data because the relevant questions are only asked every other year in the BRFSS. These data can be joined with the census 2010 ZCTA boundary file in a GIS system to produce maps for 29 measures at the ZCTA level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software.
https://cdcarcgis.maps.arcgis.com/home/item.html?id=024cf3f6f59e49fe8c70e0e5410fe3cf
Table 10. 2011-2012 NSDUH Binge Alcohol Use in the Past Month, by Age Group and State

Table 10. Binge Alcohol Use in the Past Month, by Age Group and State: Percentages, Annual Averages Based on 2011 and 2012 NSDUHs. Results are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 529258: Butane-2,3-diol, mono-hexanoate, #1

Chemical compound data from PubChem database. IUPAC Name: (3-hydroxy-2,3-dimethylbutan-2-yl) hexanoate. Molecular Formula: C12H24O3. Molecular Weight: 216.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528424: Dihydrochalcone, 2',6'-dihydroxy-4,4'-dimethoxy, bis-TMS

Chemical compound data from PubChem database. IUPAC Name: 3-[4-methoxy-2,6-bis(trimethylsilyloxy)phenyl]-1-(4-methoxyphenyl)propan-1-one. Molecular Formula: C23H34O5Si2. Molecular Weight: 446.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
PLACES: Local Data for Better Health, Place Data 2022 release

This dataset contains model-based place (incorporated and census-designated places) level estimates for the PLACES 2022 release. PLACES covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. The dataset includes estimates for 29 measures: 13 for health outcomes, 9 for preventive services use, 4 for chronic disease-related health risk behaviors, and 3 for health status. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2020 or 2019 data, Census Bureau 2010 population data, and American Community Survey 2015–2019 estimates. The 2022 release uses 2020 BRFSS data for 25 measures and 2019 BRFSS data for 4 measures (high blood pressure, taking high blood pressure medication, high cholesterol, and cholesterol screening) that the survey collects data on every other year. More information about the methodology can be found at   www.cdc.gov/places.
Hospital Inpatient Discharges (SPARCS De-Identified): Maternal Sepsis by County and Demographics: 2016-2018

The dataset contains administratively identified maternal sepsis observed event counts and rates related to live births during the pregnancy, delivery, and postpartum windows by patient county and demographics between 2016 and 2018.

Maternal sepsis is a leading cause of maternal mortality in the United States and is associated with increased rates of preterm labor, preterm delivery and fetal infection and maternal chronic pain and fertility problems.  

Live births were identified from administrative coding of SPARCS acute care hospital claims between January 1, 2016 and December 31, 2018.  Sepsis events were identified from SPARCS claims linked to these live birth events through a maternal identifier and occurring during pregnancy, delivery or within 42 days postpartum.  Counts and rates are calculated within each of these thee windows separately, and also combined.

Sepsis events are quantified for ‘All Sepsis’ and ‘Severe Sepsis/Septic Shock’ (a subset of ‘All Sepsis’).  

Counts and observed rates are presented by the patient county of residence reported on the live birth claim (including a statewide total) and select maternal demographics.
Adverse Event Reporting System (AERS)

The Adverse Event Reporting System (AERS) is a computerized information database designed to support the FDA's post-marketing safety surveillance program for all approved drug and therapeutic biologic products. The FDA uses AERS to monitor for new adverse events and medication errors that might occur with these marketed products. Reporting of adverse events from the point of care is voluntary in the United States. FDA receives some adverse event and medication error reports directly from health care professionals (such as physicians, pharmacists, nurses and others) and consumers (such as patients, family members, lawyers and others). Healthcare professionals and consumers may also report these events to the products' manufacturers. If a manufacturer receives an adverse event report, it is required to send the report to FDA as specified by regulations.  The files listed on this page contain raw data extracted from the AERS database for the indicated time ranges and are not cumulative. Users of these files need to be familiar with creation of relational databases using applications such as ORACLE, Microsoft Office Access, MySQL and IBM DB2 or the use of ASCII files with SAS analytic tools. A simple search of AERS data cannot be performed with these files by persons who are not familiar with creation of relational databases.
Patent AT-E399562-T1: [Translated] USE OF MILK SERUM APOPROTEINS IN PROPHYLAXIS OR TREATMENT OF MICROBIAL OR VIRUS INFECTIONS

The present invention relates to use of a milk apoprotein or a mixture thereof to prevent or treat microbial or viral infection of the human or animal body. It is believed that this is achieved by inhibiting adhesion of potential pathogens. More preferably, at least one milk apoprotein or a mixture thereof is administered, simultaneously or sequentially, with either or both of at least one free fatty acid or a mixture thereof or a monoglyceride thereof; and/or at least one organic acid or a salt or ester thereof or a mixture thereof. The active agent(s) may be delivered by means of a pharmaceutically acceptable delivery system which includes parenteral solutions, ointments, eye drops, nasal sprays, intravaginal devices, surgical dressings, medical foods or drinks, oral healthcare formulations and medicaments for mucosal applications.
Adolescent Mental Health Service Use and Reasons for Using Services in Specialty, Educational, and General Medical Settings

This report uses 2014 National Surveys on Drug Use and Health (NSDUHs) to estimate the of prevalence of mental health service use among adolescents aged 12 to 17, the setting for the services received (i.e., specialty, education, medical), and the reasons these adolescents receive mental health services were analyzed. Estimates are presented by age subgroups among adolescents, gender, race/ethnicity, and rural residence status.
Compound 525215: Chloromethyl 6-chloroheptanoate

Chemical compound data from PubChem database. IUPAC Name: chloromethyl 6-chloroheptanoate. Molecular Formula: C8H14Cl2O2. Molecular Weight: 213.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526975: (10,13-Dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl) butanoate

Chemical compound data from PubChem database. IUPAC Name: (10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl) butanoate. Molecular Formula: C23H36O3. Molecular Weight: 360.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece

Background
          Health Related Quality of Life (HRQoL) is an important outcome measure in Inflammatory Bowel Disease (IBD). The aim of our study was to assess HRQoL in a population of 135 Greek patients with IBD.
        
        
          Methods
          A cohort of 135 patients with IBD, 81 with ulcerative colitis (UC) and 54 with Crohn's disease (CD) were enrolled in our study. Demographic and disease-related data were recorded. HRQoL was assessed by a disease-specific and a generic questionnaire, IBDQ and SF-36, respectively. Disease activity was assessed by Harvey-Bradshaw Index and the Colitis Activity Index for CD and UC patients, respectively.
        
        
          Results
          Among all variables recorded in our study, only disease activity had a significant effect on HRQoL. Patients with active disease scored significantly lower on both IBDQ and SF-36 when compared to those in remission. Only two among the four IBDQ dimensions, bowel and systemic, had significant ability in distinguishing best patients in remission from those with active disease.
        
        
          Conclusions
          IBD has a negative impact on HRQoL. Patients with active disease are more impaired than patients in remission. In our population of patients bowel and systemic dimensions had a predominant value in patients' perception of quality of life. Patients in our study using the same instrument scored higher than previously reported.
Exposure to emissions generated by 3-dimensional printing with polycarbonate affects vascular morphology and expression of markers of oxidative stress and vascular dysfunction in cardiac tissue

Three-dimensional (3D) printing is increasingly being used in manufacturing settings, homes and schools.  Fused deposition modeling (FDM) 3D printers are the most widely used systems with standard thermoplastics such as acrylonitrile butadiene styrene (ABS), polylactic acid and polycarbonate (PC) commonly used in the manufacturing processes.  Heating of the thermoplastic generates and releases particulates and fumes.  Emission constituents frequently measured include aldehydes, benzene, toluene, ethylbenzene, and xylenes.  Inhalation of the emitted particulates and/or the fumes, that contain bisphenol A (BPA)  may pose health problems to users of these systems as well as bystanders.

The goal of the current study was to examine the effects of inhalation of PC-emissions generated during 3D-printing.  PC-emissions can include bisphenol A (BPA). Bisphenols are known endocrine and metabolic disruptors (i.e., they interfere with actions of steroid and thyroid hormones) and have been shown to have significant effects on a number of physiological systems including the endocrine and cardiovascular systems.  Because steroid hormones have major effects on cardiovascular function, it is possible that inhalation of PC particulate and/or BPA impact cardiovascular function.

To begin to understand how inhalation of PC-emissions generated during 3D printing might affect the cardiovascular system, the current study examined the effects of inhaling PC-emissions after 1, 4, 8, 15 and 30d of exposure, on peripheral vascular responses to vaso-modulating agents, on cardiac morphology and on the expression of proteins and transcripts that are markers of inflammation, oxidative stress and cardiovascular dysfunction.
Support Vector Machines for predicting protein structural class

Background
          We apply a new machine learning method, the so-called Support Vector Machine method, to predict the protein structural class. Support Vector Machine method is performed based on the database derived from SCOP, in which protein domains are classified based on known structures and the evolutionary relationships and the principles that govern their 3-D structure.
        
        
          Results
          High rates of both self-consistency and jackknife tests are obtained. The good results indicate that the structural class of a protein is considerably correlated with its amino acid composition.
        
        
          Conclusions
          It is expected that the Support Vector Machine method and the elegant component-coupled method, also named as the covariant discrimination algorithm, if complemented with each other, can provide a powerful computational tool for predicting the structural classes of proteins.
Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey

Background
          Venous thromboembolism (VTE) confers considerable morbidity and mortality in hospitalized patients, although few studies have focused on the critically ill population. The objective of this study was to understand current approaches to the prevention and diagnosis of deep venous thrombosis (DVT) and pulmonary embolism (PE) among patients in the intensive care unit (ICU).
        
        
          Design
          Mailed self-administered survey of ICU Directors in Canadian university affiliated hospitals.
        
        
          Results
          Of 29 ICU Directors approached, 29 (100%) participated, representing 44 ICUs and 681 ICU beds across Canada. VTE prophylaxis is primarily determined by individual ICU clinicians (20/29, 69.0%) or with a hematology consultation for challenging patients (9/29, 31.0%). Decisions are usually made on a case-by-case basis (18/29, 62.1%) rather than by preprinted orders (5/29, 17.2%), institutional policies (6/29, 20.7%) or formal practice guidelines (2/29, 6.9%). Unfractionated heparin is the predominant VTE prophylactic strategy (29/29, 100.0%) whereas low molecular weight heparin is used less often, primarily for trauma and orthopedic patients. Use of pneumatic compression devices and thromboembolic stockings is variable. Systematic screening for DVT with lower limb ultrasound once or twice weekly was reported by some ICU Directors (7/29, 24.1%) for specific populations. Ultrasound is the most common diagnostic test for DVT; the reference standard of venography is rarely used. Spiral computed tomography chest scans and ventilation–perfusion scans are used more often than pulmonary angiograms for the diagnosis of PE. ICU Directors recommend further studies in the critically ill population to determine the test properties and risk:benefit ratio of VTE investigations, and the most cost-effective methods of prophylaxis in medical–surgical ICU patients.
        
        
          Interpretation
          Unfractionated subcutaneous heparin is the predominant VTE prophylaxis strategy for critically ill patients, although low molecular weight heparin is prescribed for trauma and orthopedic patients. DVT is most often diagnosed by lower limb ultrasound; however, several different tests are used to diagnose PE. Fundamental research in critically ill patients is needed to help make practice evidence-based.
Arizona (AZ)

This report presents Arizona\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Arizona for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Guidance to tribes on the Submission of the first APSR to the 2025-2029 CFSP, CFS-101 Parts 1, 2 and 3

This Program Instruction (PI) provides guidance to Indian Tribes, Indian Tribal Organizations and Indian Tribal Consortia on actions they are required to take to receive their allotments authorized under title IV-B, subparts 1 and 2, and Chafee and ETV programs for Federal Fiscal Year (FY) 2026 (subject to the availability of appropriations) under the formula grant programs authorized by title IV-B, subparts 1 and 2, and the Chafee and ETV programs.

This PI summarizes requirements for completing and submitting: (1) the first APSR update to the 2025-2029 CFSP and (2) the CFS-101, Parts I, II, and III.

PI-25-02 (PDF)

For the best access to each attachment, please download and save them to your computer.

FY 2024 Allotment for Title IV-B, Subpart 1 Stephanie Tubbs Jones Child Welfare Services GrantsFY 2024 Allotment for Title IV-B, Subpart 2 Promoting Safe and Stable Families GrantsFY 2024 Allotment for Title IV-B, Subpart 2 Kinship Navigator GrantsFY 2024 Allotment for Chafee Foster Care Program for Successful Transition to Adulthood GrantsFY 2024 Allotment for Education and Training Vouchers GrantsFY 2024 Allotment for Family First Prevention Services Act Transition Grants

CFS-101 Instructions, Part I, II, and III (PDF)

IntroductionPart I: Annual Budget Request for Title IV-B, Subpart 1 & 2 Funds, CAPTA, Chafee, and ETV InstructionsPart II: Annual Estimated Expenditure Summary of Child and Family Services InstructionsPart III:  Expenditures for Title IV-B, Subparts 1 and 2, John H. Chafee Foster Care Program for Successful Transition to Adulthood, and Education and Training Voucher (ETV) Program

CFS-101 Forms, Parts I, II and III Excel Workbook (XLSX)

Annual Reporting of Education and Training Vouchers Awarded (PDF)

Certification of Tribal Population Under Age 21 (PDF)

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 526502: Acetylsalicylic acid, TBDMS

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-acetyloxybenzoate. Molecular Formula: C15H22O4Si. Molecular Weight: 294.42. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E39951-T1: [Translated] PROCESS FOR PRODUCTION OF CORROSION PREVENTING PARTICLES.

A process for producing corrosion inhibiting particles comprising binding corrosion inhibiting cations by ion-exchange to particles of silica or alumina, which preferably have a BET surface area of at least 500 m<sup>2</sup>/g, to form cation exchanged particles, the cations of which are releaseable by further ion-exchange, the BET surface area of the cation-exchanged particles being reduced, preferably to less than 150m<sup>2</sup>/g, by subjecting the cation-exchanged particles to a heat treatment which comprises heating the particles at a temperature of from 50 to 120°C while maintaining the water content of the particles at more than 15% by weight, followed by heating with removal of water to dry the particles. An embodiment of the invention comprises heating a slurry of the cation exchanged particles followed by drying e.g. spray drying.
Patent AT-E400680-T1: [Translated] SUPPORT DISC FOR SUPPORTING A ROTOR ON AN OPEN-END SPINNING MACHINE AND METHOD FOR PRODUCING THE SAME

The supporting disk (1) has a first supporting ring (3) on the periphery of a bearing ring (2) and being made of an elastic polymeric material. A side ring (7) provided on the first side of the bearing ring is disposed at a distance from the outer edge of the bearing ring. A second supporting ring (10) is provided on the periphery of the side ring. Holding members (9) connect the side ring to the bearing ring. An independent claim is also included for a method for manufacturing a supporting disk for providing bearing support to a rotor of an open-end spinning machine.